Shire on hold by Merrill

Merrill Lynch analyst Robin Campbell rated Shire Pharmaceuticals plc at hold ahead of the company's second-quarter financial results. The company is balancing strong fundamentals and significant risks, along with its ADHD franchise, according to the analyst, with possible surprises in 2006/2007. Shares of the Basingstoke, U.K.-based specialty pharmaceutical company were up $1.53, or 3.32%, at $47.61 on volume of 1,202,945 shares versus the three-month running average of 506,338 shares. (Nasdaq: SHPGY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.